Farber disease is an extremely rare, progressive lysosomal storage disease inherited in an autosomal recessive pattern. It is caused by a deficiency of the enzyme acid ceramidase, which normally breaks down the fatty substance ceramide into sphingosine and a fatty acid. When the enzyme is missing or deficient, ceramide accumulates inside the lysosomes of cells, and this buildup gives rise to the signs and symptoms of the disorder. The condition is also known as Farber lipogranulomatosis, acid ceramidase deficiency, lipogranulomatosis and ASAH1-related disorders. This entry records the classification, cause and alternative names given in the lead of the cited English Wikipedia article and does not offer medical advice.
Facts
Classification
ICD-10 ChapterIV: Endocrine, Nutritional and Metabolic Diseases 1 Communicable or Non-communicable Causative Agent
Causative Agent (category) Sources
1. World Health Organization: ICD-10 Version:2019 - E70-E90 Metabolic disorders
World Health OrganizationICD-10 2019 category E75.2, Chapter IV (condition-kind)Quote, ICD-10 2019 category E75.2, Chapter IV (condition-kind)
E75.2 Other sphingolipidosis Incl.: Disease: Fabry(-Anderson) Gaucher Krabbe Niemann-Pick Farber syndrome
View the Source 2. Farber disease (Wikipedia)
Lead
autosomal recessive lysosomal storage disease caused by a deficiency of the acid ceramidase enzyme
Lead: disease category
Farber disease (also known as Farber's lipogranulomatosis, acid ceramidase deficiency, "Lipogranulomatosis", and ASAH1-related disorders) is an extremely rare, progressive, autosomal recessive lysosomal storage disease caused by a deficiency of the acid ceramidase enzyme.
View the SourceNational Library of Medicine: MeSH Descriptor Data: Farber Lipogranulomatosis
National Library of MedicineMeSH tree number C10.228.140.163.100.435.825.250Quote, MeSH tree number C10.228.140.163.100.435.825.250
A sphingolipidosis subtype that is characterized by the histological appearance of granulomatous deposits in tissues.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.